Good publication practice for pharmaceutical companies.
نویسندگان
چکیده
Guidelines on Good Publication Practice (GPP) for pharmaceutical companies are presented. The aim of the guidelines is to ensure that clinical trials sponsored by pharmaceutical companies are published in a responsible and ethical manner. The guidelines cover companies' responsibility to an endeavour to publish results of all studies, companies' relations with investigators, measures to prevent redundant or premature publication, methods to improve trial identification and the role of professional medical writers. Our aim in publishing the GPP guidelines, which are the first to be developed by and for those working on publications in the pharmaceutical industry, is to stimulate discussion between journals, investigators and trial sponsors and to provide guidance to those who seek it. We also hope that pharmaceutical companies and others involved in developing publications arising from sponsored clinical trials will endorse the guidelines.
منابع مشابه
Good publication practices for pharmaceutical companies: why we need another set of guidelines.
Peer-reviewed publication is an integral part of biomedical research; yet, although the conduct of trials sponsored by pharmaceutical companies is closely regulated by Good Clinical Practice (GCP), their reporting had, until now, no such framework. Journal editors have highlighted the problems that can arise if the relationship between sponsor companies and academic investigators is abused. In ...
متن کاملGood Publication Practice for Communicating Company-Sponsored Medical Research: GPP3.
This updated Good Publication Practice (GPP) guideline, known as GPP3, builds on earlier versions and provides recommendations for individuals and organizations that contribute to the publication of research results sponsored or supported by pharmaceutical, medical device, diagnostics, and biotechnology companies. The recommendations are designed to help individuals and organizations maintain e...
متن کاملGood Laboratory Practice (GLP) status of Asian countries and its implementation in non-clinical safety studies in pharmaceutical drug development.
Non-clinical animal studies to assess the safety of compounds under development have to comply with Good Laboratory Practice (GLP). The Organization for Economic Co-operation and Development (OECD) has established the Mutual Acceptance of Data (MAD) system in OECD member countries for the mutual acceptance of non-clinical safety study data. Since 1997 non-OECD-member countries have also been ab...
متن کاملSketching Out the Hidden Lean Management Principles in the Pharmaceutical Manufacturing
In Recent times, pharmaceutical companies are faced with the demanding tasks such as adjustments to the unstable and turbulent market in times of economic crisis as well as to meet the customer needs. The pharmaceutical industry, manufacturing in a current Good manufacturing practice (cGMP) environment has been slow to adopt the lean manufacturing unlike many sectors where it has been successfu...
متن کاملCost benefit of investment on quality in pharmaceutical manufacturing: WHO GMP pre- and post-certification of a Nigerian pharmaceutical manufacturer
BACKGROUND Pharmaceutical companies in Africa need to invest in both facilities and quality management systems to achieve good manufacturing practice (GMP) compliance. Compliance to international GMP standards is important to the attainment of World Health Organization (WHO) prequalification. However, most of the local pharmaceutical manufacturing companies may be deterred from investing in qua...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Current medical research and opinion
دوره 19 3 شماره
صفحات -
تاریخ انتشار 2003